A Message from Our CEO, Dr. Jonathan Kaufman – Advancing LP-310 for Oral Lichen Planus

As CEO of Lipella Pharmaceuticals, I am thrilled to share an important milestone in our clinical development: The topline results from our Phase 2a study of LP-310, a novel oral rinse formulation for Oral Lichen Planus (OLP), are highly encouraging. We are excited to announce that the trial demonstrated statistically significant reductions in pain, ulceration, and inflammation while reinforcing LP-310’s strong safety and tolerability profile. This represents a meaningful step forward in our mission to develop effective treatment options for chronic, painful inflammatory conditions that currently lack FDA-approved therapies.

OLP affects six to seven million Americans and remains a largely underserved condition. The topline results from our first cohort reinforce the potential of LP-310 as a targeted, localized therapy designed to address and surpass the limitations of current palliative treatments, such as topical steroids. With no approved pharmacotherapy available for OLP today, we genuinely believe LP-310 has the potential to transform the treatment landscape for patients suffering from this chronic autoimmune disease.

We remain committed to advancing LP-310 through its clinical development with a focus on delivering innovative solutions that improve patient outcomes. Our team continues to work diligently to build upon this momentum, and we look forward to further progress in the clinical program.

I am incredibly excited about the continued development of LP-310 and what it could mean for patients with OLP. We believe this program represents a significant opportunity to bring a much-needed therapeutic option to a community in need of treatment, recognition, and support.

Thank you to our patients, investigators, and stakeholders for your continued support. Together, we are driving forward a new era in the treatment of Oral Lichen Planus.

Warm regards,
Jonathan Kaufman
CEO, Lipella Pharmaceuticals